← All FR Documents ·← Back to 2024-04526
Notice

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Monthly Implementation Assessment

In Plain English

What is this Federal Register notice?

This is a notice published in the Federal Register by Health and Human Services Department, Food and Drug Administration. Notices communicate information, guidance, or policy interpretations but may not create new binding obligations.

Is this rule final?

This document is classified as a notice. It may or may not create enforceable regulatory obligations depending on its specific content.

Who does this apply to?

Consult the full text of this document for specific applicability provisions. The affected parties depend on the regulatory scope defined within.

When does it take effect?

No specific effective date is indicated. Check the full text for date provisions.

Why it matters: This notice communicates agency policy or guidance regarding applicable regulations.

Document Details

Document Number2025-12420
TypeNotice
PublishedJul 3, 2025
Effective Date-
RIN-
Docket IDDocket No. FDA-2023-N-0894
Text FetchedYes

Agencies & CFR References

CFR References:
None

Linked CFR Parts

PartNameAgency
No linked CFR parts

Paired Documents

TypeProposedFinalMethodConf
No paired documents

Related Documents (by RIN/Docket)

Doc #TypeTitlePublished
2024-04526 Notice Agency Information Collection Activities... Mar 5, 2024

External Links

📋 Extracted Requirements 0 found

No extractable regulatory requirements found in this document. This is common for documents that:

  • Incorporate requirements by reference (IBR) to external documents
  • Are procedural notices without substantive obligations
  • Contain only preamble/explanation without regulatory text

Full Document Text (2,131 words · ~11 min read)

Text Preserved
<NOTICE> DEPARTMENT OF HEALTH AND HUMAN SERVICES <SUBAGY>Food and Drug Administration</SUBAGY> <DEPDOC>[Docket No. FDA-2023-N-0894]</DEPDOC> <SUBJECT>Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Monthly Implementation Assessment</SUBJECT> <HD SOURCE="HED">AGENCY:</HD> Food and Drug Administration, HHS. <HD SOURCE="HED">ACTION:</HD> Notice. <SUM> <HD SOURCE="HED">SUMMARY:</HD> The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. </SUM> <DATES> <HD SOURCE="HED">DATES:</HD> Submit written comments (including recommendations) on the collection of information by August 4, 2025. </DATES> <HD SOURCE="HED">ADDRESSES:</HD> To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <E T="03">https://www.reginfo.gov/public/do/PRAMain.</E> Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The title of this information collection is “The Real Cost Monthly Implementation Assessment.” Also include the FDA docket number found in brackets in the heading of this document. <FURINF> <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD> Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, <E T="03">PRAStaff@fda.hhs.gov.</E> </FURINF> <SUPLINF> <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD> In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. <HD SOURCE="HD1">The Real Cost Monthly Implementation Assessment</HD> <HD SOURCE="HD2">OMB Control Number 0910—NEW</HD> This information collection supports the development and implementation of FDA public education campaigns related to tobacco use. To reduce the public health burden of tobacco use in the United States and educate the public—especially young people—about the dangers of tobacco use, the FDA Center for Tobacco Products (CTP) is developing and implementing multiple public education campaigns. FDA launched “The Real Cost” in February 2014, seeking to reduce tobacco use among at-risk teens ages 12-17 in the United States who are open to using tobacco products, or who have already experimented with tobacco products. Complementary evaluation studies, including the “Evaluation of FDA's Public Education Campaign on Teen Tobacco (ExPECTT),” were implemented to measure awareness of “The Real Cost” paid media campaign among teens ages 12-17 in the United States, and to understand how awareness is related to change in key outcomes. Although outcome evaluation studies of “The Real Cost” have and continue to assess the impact of awareness on outcomes, no studies have sought to assess the implementation of “The Real Cost.” As FDA continues to increase the presence of “The Real Cost” on digital channels ( <E T="03">e.g.,</E> Hulu, YouTube, Instagram), the need for an implementation evaluation has become clear as these messages are received by the target audience on digital channels differently compared to how the messages are received on broadcast channels. Before the migration of campaign ads to digital channels, ads from “The Real Cost” were primarily aired on broadcast TV. In the broadcast space, for people to avoid receiving the message, they needed to be proactive ( <E T="03">e.g.,</E> finding the remote to change the channel or leaving the room). In the digital space, however, people need to be proactive to watch the full message, like stopping scrolling on social media or watching the full ad on YouTube. Assessment of this information is integral to understanding self-reported ad awareness levels, as well as how our audience experiences and processes the ads as they are airing in a digital setting. Therefore, we propose to establish an umbrella generic ICR to help us understand, in a digital setting, how teens experience the messages, how they engage with messages, the extent to which teens report being exposed to messages, and how teens process the messages. Data gathered from this assessment will also provide the necessary and timely information to optimize campaign messages, the digital media buy ( <E T="03">i.e.,</E> where, how, and when ads are shown), and creative rotations ( <E T="03">i.e.,</E> which ads are shown). “The Real Cost” Monthly Implementation Assessment (MIA) umbrella generic is a mixed methods generic information collection (gen IC) mechanism that will be conducted using virtual discussion groups or interviews, as well as web-based surveys that are self-administered on personal computers or web enabled mobile devices to collect rapid data on “The Real Cost” stimuli. Survey data from up to 2,000 teens in the United States will be collected each month for up to 24 months. To be eligible, participants must be between the ages of 12-20 and have not taken the MIA survey within the past 3 months. Mixed methods data from up to 400 participants ages 12-20 years in the United States will be collected on a quarterly basis ( <E T="03">i.e.,</E> collected an average of four times a year). Participants will only be eligible to participate in an MIA mixed methods study if they have not already participated within the past year. We will use an Ipsos Knowledge Panel to collect data on “The Real Cost” stimuli. This design offers flexibility to assess new stimuli messages, as they air across various digital platforms, examine their performance over time, as well as the ability to pivot and add new survey measures as necessary. Monthly data will also allow us to obtain timely information on stimuli awareness, perceived effectiveness, as well as on teen attention and processing of the stimuli. The purpose of FDA's “The Real Cost” MIA generic information collection is to evaluate the following key components about “The Real Cost” stimuli: • Awareness of “The Real Cost” brand and stimuli. • Attention behaviors when seeing “The Real Cost” stimuli. • Processing of “The Real Cost” stimuli, including: ○ Engagement with the stimuli. ○ Main message comprehension. ○ Acceptance and/or rejection of the stimuli. • Perceived effectiveness of “The Real Cost” stimuli. • Potential unintended consequences of viewing “The Real Cost” stimuli. In addition to the above components, the gen IC study will ask participants to report on tobacco use and other psychographic and demographic items. The time frame that the survey items will ask about for stimuli awareness ( <E T="03">i.e.,</E> past 30 days or past week) will depend on several factors, including how long the stimuli was on air. Each gen IC survey will take an average of approximately 25 minutes to complete per participant. As the survey items are tested, any irrelevant items will be cut as necessary. Stimuli creative for cigarette products and emerging tobacco products ( <E T="03">e.g.,</E> electronic nicotine delivery systems or ENDS) will be assessed; therefore, two similar surveys (one on ENDS-focused or emerging tobacco product stimuli and one on cigarette-focused stimuli) will be fielded as appropriate, but not within the same month. In support of the provisions of the Tobacco Control Act that require FDA to protect the public health and to reduce tobacco use by minors, FDA requests OMB approval to collect information to evaluate CTP's public education campaign “The Real Cost” through the MIA under an umbrella generic information collection. In the <E T="04">Federal Register</E> of April 27, 2023 (88 FR 25660), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: <GPOTABLE COLS="6" OPTS="L2,nj,p7,7/8,i1" CDEF="s50,12,12,9,xs72,7"> <TTITLE> Table 1—Estimated Annual Reporting Burden  <SU>1</SU> </TTITLE> <CHED H="1">Type of respondent; activity</CHED> <ENT>0.05 (3 minutes)</ENT> <ENT>122,866</ENT> </ROW> <ROW> <ENT I="01">Parent Permission</ENT> <ENT>1,842,983</ENT> <ENT>1</ENT> <ENT>1,842,983</ENT> <ENT>0.05 (3 minutes)</ENT> <ENT>92,149</ENT> </ROW> <ROW> <ENT I="01">Each Invitation Emails (Respondents ages 18-20)</ENT> <ENT>54,577</ENT> <ENT>1</ENT> <ENT>54,577</ENT> <ENT>0.02 (1 minute)</ENT> <ENT>1,092</ENT> </ROW> <ROW> <ENT I="01">Youth Assent</ENT> <ENT>29,836</ENT> <ENT>1</ENT> <ENT>29,836</ENT> <ENT>0.05 (3 minutes)</ENT> <ENT>1,492</ENT> </ROW> <ROW> <ENT I="01">Young Adult Consent</ENT> <ENT>21,364</ENT> <ENT>1</ENT> <ENT>21,364</ENT> <ENT>0.05 (3 minutes)</ENT> <ENT>1,068</ENT> </ROW> <ROW> <ENT I="01">Online Survey</ENT> <ENT>48,000</ENT> <ENT>1</ENT> <ENT>48,000</ENT> <ENT>0.42 (25 minutes)</ENT> <ENT>20,160</ENT> </ROW> <ROW> <ENT I="01">Mixed Methods (Online Survey + Virtual Discussion Group or Interview)</ENT> <ENT>3,200</ENT> <ENT>1</ENT> <ENT>3,200</ENT> <ENT>1.5 (90 minutes)</ENT> <ENT>4,800</ENT> </ROW> <ROW RUL="n,s"> <ENT I="01">Reminder Emails</ENT> <ENT>51,200</ENT> <ENT>1</ENT> <ENT>51,200</ENT> <ENT>0.20 (12 minutes)</ENT> <ENT>10,240</ENT> </ROW> <ROW> <ENT I="03">Total</ENT>  There are no capital costs or operating and maintenance costs associated with this collection of information. </TNOTE> </GPOTABLE> Data collection under the MIA umbrella generic will occur over the course of 2 years (24 months) and will consist of administering a monthly survey to approximately 2,000 participants aged 12 to 20 <E T="03">and</E> a quarterly mixed methods data collection to approximately 400 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Preview showing 10k of 15k characters. Full document text is stored and available for version comparison. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
This text is preserved for citation and comparison. View the official version for the authoritative text.